FDA Talent Hunt: Better To Recruit From Academia Than Industry?
This article was originally published in The Tan Sheet
Executive Summary
CDER Oncology office head Richard Pazdur says making FDA more academic could help with retention. In addition to fewer staff than needed to complete its work, FDA’s hiring problem makes it more difficult for the agency to stay abreast of new scientific discoveries and technology.
You may also be interested in...
FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure
Friends of Cancer Research proposes realignment of medical product functions by disease area without regard to modality; former commissioners give some support but new drugs Director Jenkins warns about unintended consequences that could negatively impact innovation and approvals.
Califf Supports Combo Products Pathway At Confirmation Hearing
FDA's concepts for new pathway could be ready for congressional scrutiny within a year.
FDA Personnel Growth Looks To Have Plateaued For Drugs Program
Only a handful of new FTEs are requested in President Obama’s FY 2016 budget request for human drugs activities, suggesting that GDUFA and other related programs may have reached their critical mass of employees for now.